256 related articles for article (PubMed ID: 31229275)
1. Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
Vokinger KN; Kesselheim AS
Health Policy; 2019 Aug; 123(8):721-727. PubMed ID: 31229275
[TBL] [Abstract][Full Text] [Related]
2. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
Eckert JC
Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
[TBL] [Abstract][Full Text] [Related]
4. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Yamashita K; Kaneko M; Narukawa M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
[TBL] [Abstract][Full Text] [Related]
5. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
[TBL] [Abstract][Full Text] [Related]
6. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
Mostaghim SR; Gagne JJ; Kesselheim AS
BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
[No Abstract] [Full Text] [Related]
7. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.
Ladanie A; Schmitt AM; Speich B; Naudet F; Agarwal A; Pereira TV; Sclafani F; Herbrand AK; Briel M; Martin-Liberal J; Schmid T; Ewald H; Ioannidis JPA; Bucher HC; Kasenda B; Hemkens LG
JAMA Netw Open; 2020 Nov; 3(11):e2024406. PubMed ID: 33170262
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
9. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
10. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate.
Chen EY; Raghunathan V; Prasad V
JAMA Intern Med; 2019 Jul; 179(7):915-921. PubMed ID: 31135822
[TBL] [Abstract][Full Text] [Related]
11. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
Hsiue EH; Moore TJ; Alexander GC
Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
[TBL] [Abstract][Full Text] [Related]
12. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
13. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
[TBL] [Abstract][Full Text] [Related]
14. Seamless Oncology-Drug Development.
Prowell TM; Theoret MR; Pazdur R
N Engl J Med; 2016 May; 374(21):2001-3. PubMed ID: 27074059
[No Abstract] [Full Text] [Related]
15. Oncologic Drugs Advisory Committee Recommendations and Approval of Cancer Drugs by the US Food and Drug Administration.
Tibau A; Ocana A; Anguera G; Seruga B; Templeton AJ; Barnadas A; Amir E
JAMA Oncol; 2016 Jun; 2(6):744-50. PubMed ID: 26940233
[TBL] [Abstract][Full Text] [Related]
16. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
17. Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
Ladanie A; Speich B; Briel M; Sclafani F; Bucher HC; Agarwal A; Ioannidis JPA; Pereira TV; Kasenda B; Hemkens LG
J Clin Epidemiol; 2019 Oct; 114():49-59. PubMed ID: 31158450
[TBL] [Abstract][Full Text] [Related]
18. Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies.
Gafter-Gvili A; Tibau A; Raanani P; Shepshelovich D
Acta Haematol; 2020; 143(1):73-77. PubMed ID: 31167178
[TBL] [Abstract][Full Text] [Related]
19. Benefit, burden, and impact for a cohort of post-approval cancer combination trials.
Carlisle BG; Doussau A; Kimmelman J
Clin Trials; 2020 Feb; 17(1):18-29. PubMed ID: 31580145
[TBL] [Abstract][Full Text] [Related]
20. Use of Real-World Evidence to Support FDA Approval of Oncology Drugs.
Feinberg BA; Gajra A; Zettler ME; Phillips TD; Phillips EG; Kish JK
Value Health; 2020 Oct; 23(10):1358-1365. PubMed ID: 33032780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]